Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has partnered with a cannabis use tracking app to help patients understand which cultivars, THC/CBD levels, methods and doses work best for them.
On Wednesday, the cannabis giant announced the partnership with Strainprint App which will be used by patients to journal and log their symptoms and consumption habits. Patients can also explore new products and see what has helped other patients in the past.
“We take a patient-first approach to cannabis and are proud to provide our patients with programs that improve their lives and their medical cannabis journey,” says Mike Jones, SVP of Medical at Aurora Cannabis.
“By working with Strainprint, we can support our patients every step of the way, and further Aurora’s promise to prioritize patient well-being and provide the highest quality products.”
Strainprint is an analytics technology platform that has provided data to patients, doctors, licensed producers, retailers, industry regulators, academic researchers and pharmaceutical/biotechnology companies across Canada, the U.S., Australia, Israel and New Zealand. The app has been used to track information about cannabis consumption in previous clinical studies.
Read more: Aurora Cannabis expands Australian portfolio with new high THC product
Read more: Tilray reports $1.1B in losses during Q3 2023, acquires Hexo for $75M
Last August, Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) released launched CannaPoints under the Strainprint App, a new program designed to support patients through their medical cannabis journey. Patients are also able to earn points via the app and get discounts for products.
Other cannabis usage tracking apps include Releaf which offers similar information to patients.
NEWSLETTER
Subscribe to our newsletter
Want the best of alternative investing news including cannabis, psychedelics, technology, and trending industries sent to your inbox?
Sign up to get our stories of the week sent to your inbox.
We will never sell your information or spam you. By entering your email, you are agreeing to our terms of use and understand our privacy policy.
